Grahek D, Hassan-Sebbag N
Hôpital Henri-Duffaut, Service de Médecine Nucléaire, 305 Rue Raoul-Follereau, 84902 Avignon Cedex 09, France.
Bull Cancer. 2009 Dec;96(12):1163-71. doi: 10.1684/bdc.2009.0983.
Despite technical advances in many areas of diagnostic radiology, the detection and imaging of advanced-stage ovarian carcinoma remains a challenge. The metabolic imaging using positron-emission tomography (PET), more recently integrated PET/CT can provide a different perspective and contribute to a best understanding of the disease. After to describe the advantages and the limits of this technology, this review reports the performances of FDG-PET in recent studies, in different settings: initial staging, restaging, detection of recurrences and predicting response to chemotherapy. PET imaging appears, like in others cancers, to be specially useful for the diagnosis of recurrence, when clinical or radiological recurrence is suspected or when CA125 levels are rising. Moreover, it influence significantly the patient management. But this imaging can also improve the detection of lesions in others settings, and we considers this potential impact treatment, particularly when a optimal surgery is indicated. At the end, PET with FDG or others tracers could be using to predict the early response to systemic therapy and to stop quickly an inefficient treatment.
尽管诊断放射学的许多领域都有技术进步，但晚期卵巢癌的检测和成像仍然是一项挑战。使用正电子发射断层扫描（PET）的代谢成像，最近整合的PET/CT可以提供不同的视角，并有助于更好地理解该疾病。在描述了这项技术的优点和局限性之后，本综述报告了FDG-PET在近期不同情况下的研究表现：初始分期、再分期、复发检测以及预测化疗反应。与其他癌症一样，PET成像在怀疑临床或放射学复发或CA125水平升高时，似乎对复发诊断特别有用。此外，它对患者管理有显著影响。但这种成像也可以改善其他情况下病变的检测，我们认为这对治疗有潜在影响，特别是在需要进行最佳手术时。最后，使用FDG或其他示踪剂的PET可用于预测对全身治疗的早期反应，并迅速停止无效治疗。
